<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474276</url>
  </required_header>
  <id_info>
    <org_study_id>2014-062</org_study_id>
    <secondary_id>FPC N° 2013-4025</secondary_id>
    <nct_id>NCT03474276</nct_id>
  </id_info>
  <brief_title>Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old</brief_title>
  <acronym>MALINEA</acronym>
  <official_title>A Multi-center, Randomized Controlled Comparison of Three Renutrition Strategies for the Management of Moderate Acute Malnutrition Among Children From 6 to 24 Months (Madagascar, Niger, Central African Republic and Senegal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Action Contre la Faim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherches Médicales et Sanitaires CERMES Niger</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de Madagascar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de Bangui</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de Dakar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this open-label randomized controlled trial conducted in four African countries
      (Madagascar, Niger, Central African Republic and Senegal) is to compare three strategies of
      renutrition for moderate acute malnutrition (MAM) in children based on modulation of the gut
      microbiota with enriched flours alone, enriched flours with prebiotics or enriched flours
      coupled with antibiotic treatment. Cognitive development of children (Senegal) will also be
      studied and compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to improve the nutrition strategy used to take in charge
      moderate acute malnutrition (MAM) which is the major milestone before severe malnutrition.
      This will be based on the modulation of the gut microbiota with adjunct product added to
      standard nutrition flours.

      The purpose of the MALINEA study is to compare three management strategies for Moderate Acute
      Malnutrition (MAM) in children aged between 6 months and 2 years old on recovery defined by a
      weight/size gain at 3 months.

      The 3 groups will be compared on several anthropometric measurements [Weight, length, Mid
      Upper Arm Circumference (MUAC)], clinical characteristics, adherence and tolerance to
      interventions between before and after a 3 months intervention Cognitive development of
      children (Senegal) will also be studied and compared, at inclusion, 3 months and 6 months
      after inclusion.

      The investigators will also investigate the microbiomes of malnourished children at inclusion
      and at 3 and 6 months after inclusion to compare it to the ones of normonourished children.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery at three month</measure>
    <time_frame>Three month</time_frame>
    <description>Recovery at three months, defined by: Weight/Size Z-score ≥ -1.5 SD measured at 2 following consultations without hospitalization, transfer, death or lost to follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive-motor development (Senegal)</measure>
    <time_frame>Baseline, three, six and nine months after inclusion</time_frame>
    <description>Developmental Milestones Checklist II (DMC II) questionnaire to evaluate participating children cognitive and motor abilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Operational Taxonomic Unit composition of stool samples according to the nutritional status</measure>
    <time_frame>Baseline, three and six months after inclusion</time_frame>
    <description>Each sample will be ADN extracted using Quiagen technology 16S and 18S amplification will be conducted following Hughert et al. (2014) and Tang et al. (2015). PCR products will be sequenced using NGS Illumina plateform. Sequences will be analyzed using Mothur 1.37.6 software and Silva data base (https://www.arb-silva.de/browser). OTU (Operational Taxonomic Unit) composition will be determined for each sample.
OTU composition of samples from well and malnourished children will be compared using mann whitney test, and shift in OTUs during renutrition will be analysed using survival analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1320</enrollment>
  <condition>Moderate Acute Malnutrition</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).
200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azythromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azythromycin</intervention_name>
    <description>Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days</description>
    <arm_group_label>Azythromycin</arm_group_label>
    <other_name>Antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inuline and fructo-oligosaccharides</intervention_name>
    <description>Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.</description>
    <arm_group_label>Prebiotic</arm_group_label>
    <other_name>Prebiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Administration of Albendazole at inclusion of the child : 200mgs, one administration</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Azythromycin</arm_group_label>
    <arm_group_label>Prebiotic</arm_group_label>
    <other_name>Antiparasitic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fortified blend flour</intervention_name>
    <description>Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day
Compostion of the fortified blend flour per 100 grams : either :
Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Azythromycin</arm_group_label>
    <arm_group_label>Prebiotic</arm_group_label>
    <other_name>Lacteal flour</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged from 6 to 24 months olds.

          -  Moderate acute malnutrition defined by a -3 ≤ Weight/Height z-score &lt; -2 SD.

          -  Written informed consent of parents or legal guardian.

          -  Child able to be brought back to the centre on the two following days of inclusion.

          -  Child able to be followed up during at least three months.

        Exclusion Criteria:

          -  Severe malnutrition defined by a mid upper arm circumference &lt; 115 mm OR Weight/Height
             z-score &lt; -3 SD OR presence of nutritional oedema.

          -  Clinical complications or according to the physician any clinical sign requiring care
             outside of the recruitment centre (referral to specialised centre or hospitalisation)

          -  Diarrhea with mucus and bloody stools.

          -  Current incompatible treatment : Antacids, Cetirizine, Digoxin, Ergotamine,
             Azidothymidine.

          -  Known hypersensitivity to macrolides or albendazole (or one of its components)

          -  Known allergy to enriched flours or prebiotics used in the study, or one of its
             components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronan JAMBOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel Vray, PhD</last_name>
    <phone>+221 33 839 92 47</phone>
    <email>mvray@pasteur.sn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassandre von Platen</last_name>
    <phone>+33 1 45 68 89 91</phone>
    <email>cassandre.von-platen@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Pasteur de bangui - Centre Nutritionnel de Gbangouma et Centre de Santé Saint-Joseph</name>
      <address>
        <city>Bangui</city>
        <zip>BP 923</zip>
        <country>Central African Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Manirakiza</last_name>
      <phone>+236 70930579</phone>
      <email>alexandre.manirakiza@pasteur-bangui.org</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Pierre Lombart</last_name>
      <phone>+236 72 05 97 17</phone>
      <email>jean-pierre.lombart@pasteur.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de Madagascar - CRENAM Andohotapenaka et Centre de Santé Mitia</name>
      <address>
        <city>Antananarivo</city>
        <zip>101</zip>
        <country>Madagascar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rindra RANDREMANANA, MD PhD</last_name>
      <phone>+261 20 22 412 72</phone>
      <phone_ext>229</phone_ext>
      <email>rrandrem@pasteur.mg</email>
    </contact>
    <contact_backup>
      <last_name>Rojovola RAKOTONDRAMANANA</last_name>
      <phone>+261 20 22 412 72</phone>
      <phone_ext>126</phone_ext>
      <email>rojovola@pasteur.mg</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de santé intégré ACF de Tchake et d'Issawanne</name>
      <address>
        <city>Maradi</city>
        <country>Niger</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdias Ogobara DOUGNON, MD, MPH</last_name>
      <phone>+227 20 75 30 79</phone>
      <email>adougnon@ne.acfspain.org</email>
    </contact>
    <contact_backup>
      <last_name>Abdal-Aziz Dr OUSMAN GADO</last_name>
      <email>agado@ne.acfspain.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de Dakar - Poste de Santé Hamo V</name>
      <address>
        <city>Dakar</city>
        <state>Guédiawaye</state>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Gildas Hédible, MD MPH</last_name>
      <phone>+221 33 839 92 46</phone>
      <email>Gildas.Hedible@pasteur.sn</email>
    </contact>
    <contact_backup>
      <last_name>Muriel Vray, PhD</last_name>
      <phone>+221 33 839 92 47</phone>
      <email>mvray@pasteur.sn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Central African Republic</country>
    <country>Madagascar</country>
    <country>Niger</country>
    <country>Senegal</country>
  </location_countries>
  <link>
    <url>http://www.gret.org/</url>
    <description>GRET: French development NGO fighting poverty and inequalities, providing solutions for development [150 projects per year in 30 countries]</description>
  </link>
  <link>
    <url>http://www.pasteur.fr/en</url>
    <description>Institut Pasteur: Private non-profit foundation whose mission is to prevent and treat diseases through research, teaching, and public health initiatives.</description>
  </link>
  <link>
    <url>http://www.actionagainsthunger.org</url>
    <description>Action contre la faim [Action against hunger] : International humanitarian organization providing communities with access to safe water and sustainable solutions to hunger.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Africa</keyword>
  <keyword>Metagenomic</keyword>
  <keyword>Prebiotic</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Pragmatic trial</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

